Non-opioid Pain Treatment: Global Markets to 2022

  • ID: 4466400
  • Report
  • Region: Global
  • 168 pages
  • BCC Research
15 % OFF
until Dec 31st 2018
1 of 6

FEATURED COMPANIES

  • Allergan PLC
  • Aurora
  • Canopy Growth Corp.
  • Centrexion Therapeutics
  • Cronos Group
  • Medical Marijuana Inc.
  • MORE
Report Scope:

This report is designed to be a helpful business tool that will provide a thorough evaluation of the markets for pain management. The geographical scope of this study is global. This
study addresses acute versus chronic pain, treatments and regulatory issues facing healthcare workers. Also provided is detailed information based on product categories, use of products, forecasts and
competitive analyses.

The report identifies five general product segments for non-opioid treatment of pain:
  • Medical cannabis treatments.
  • Capsaicin-derived treatments.
  • Menthol-containing treatments.
  • Omega 3 fatty acid-containing treatments.
  • Botulinum toxins.
Within the segment several sub-segments are discussed as they pertain to each product segment; diseases or disorders are the basis for these sub-segments, including:
  • Arthritis.
  • Cancer; brain, breast, colorectal, leukemia/lymphoma, melanoma, prostate, others.
  • Dental.
  • Epilepsy.
  • Fibromyalgia.
  • Migraine.
  • Multiple sclerosis.
  • Surgical.
A regional analysis of these product segments is also provided, including the specific countries listed below and including countries not listed as a “rest of the world” market.
  • Argentina.
  • Australia/New Zealand.
  • Brazil.
  • Canada.
  • China.
  • France.
  • Germany.
  • Italy.
  • Japan.
  • Mexico.
  • Russia.
  • Spain.
  • United Kingdom.
  • United States.
Each market segment provides detailed information based on product categories, product use, current market value and forecasts.

Not covered in the report are drugs or devices that are considered “conventional” in professional treatment guidelines that are due to either controversial issues such as those with medical cannabis or those that are not commonly prescribed or recommended due to a lack of clinical data, education or other factors.

Report Includes:
  • 46 data tables and 19 additional tables
  • An overview of the global market for non-opioid pain treatments
  • Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • Market breakdown by type, segment, indication, application, and country
  • Identification of segments with high growth potential and their future applications
  • Explanation of major drivers and regional dynamics of the market and current trends within the industry
  • Detailed profiles of major vendors in the market, including Allergan Plc, Aphria Inc., Canopy Growth Corp., Cara Therapeutics and Cronos Group
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Allergan PLC
  • Aurora
  • Canopy Growth Corp.
  • Centrexion Therapeutics
  • Cronos Group
  • Medical Marijuana Inc.
  • MORE
1. Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Related Reports

2. Summary and Highlights
Market Overview
Regional Market Summary
Drivers and Restraints

3. Market Overview and Background
History of Pain and Pain Treatment
Types of Pain
Physiological Pain Classifications
How Pain is Diagnosed
How Pain is Treated
Opioid vs. Non-opioid Pain Control
Alternative Methods of Pain Management
Alternative Non-opioid Therapies for Treating Pain
Medical Cannabis
Capsaicin-derived Compound
Menthol-containing Compound
Omega 3 Fatty Acid-containing Supplements
Botulinum Toxins (OnabotulinumtoxinA/RimabotulinumtoxinB)
Others
Growing Trend in Cannabis Treatment for Pain
Adoption of Medical Cannabis: A Global Analysis
Laws and Legalization Trends
Claims in Effectiveness
Potency and Validation Testing Trends
Access to Palliative Care Around the World
Assessing the Need for Palliative Care
Market Influences and Indicators of Growth

4. Market Breakdown by Product Segment
Overview
Medical Cannabis
Capsaicin-derived Therapies
Menthol-containing Therapies
Omega-3 Fatty Acid-containing Therapies
Botulinum Toxin Treatments

5. Market Breakdown by Therapeutic Application
Overview
Alternative Non-opioid Cancer Pain Treatment
Alternative Non-opioid Neuropathic Pain Treatment
Alternative Non-opioid Orthopedic/Musculoskeletal Pain Treatments
Other Alternative Non-opioid Pain Treatments

6. Market Breakdown by Region
Overview
Regional Groupings
North America
Canada
United States
EMEA
France
Germany
Italy
Russia
Spain
United Kingdom
Asia-Pacific
Australia/New Zealand
China
Japan
Latin America
Argentina
Brazil
Mexico

7. Patent Analysis
Patent Analysis Overview
Non-opioid Pain Relief Categories
Medical Cannabis
Technologies
Cannabis Patent Review by Year
Patent Review by Company
Patent Review by Major Country
Patent Review by Assignee

8. Company Profiles
ALLERGAN PLC
APHRIA INC.
AURORA
BEDROCAN
CANOPY GROWTH CORP.
CARA THERAPEUTICS
CENTREXION THERAPEUTICS
CHT MEDICAL
CRONOS GROUP
GW PHARMACEUTICALS
MEDICAL MARIJUANA INC.
MEDROPHARM GMBH
PANAG PHARMA INC.
TILRAY
US WORLDMEDS LLC
VANWAY

9. Appendix: Terminology and Sources of Information

List of Tables:
Table A: Major Countries, by Region
Summary Table: Global Market for Non-opioid Pain Treatments, by Product Segment, Through 2022
Table 1: Physiological Effects of Pain
Table 2: United States Opioid Addiction and Abuse Statistics
Table 3: Global Opioid Addiction and Abuse Statistics
Table 4: List of Brand Name Extended-release and Long-acting Opioid Products Required to be Included in Opioid REMS (Updated May 2017)
Table 5: List of Generic Extended-release and Long-acting Opioid Products Required to be Included in Opioid REMS (Updated May 2017)
Table 6: List of Transmucosal Immediate-release Fentanyl Products Required to be Included in the TIRF REMS Access Program
Table 7: Table 7 Adoption of Medical Cannabis, by Select Country (Age 15 and Over), 2017
Table 8: Medical Cannabis Programs, by U.S. State
Table 9: Top Five U.S. States with Medical Cannabis Applications/Registrations
Table 10: Effectiveness of Fibromyalgia Treatments: Cannabis vs. Pharmaceutical Therapies
Table 11: Hospice Statistics, Patient Characteristics, 2009-2014
Table 12: Hospice Statistics, Patients, by Primary Diagnosis, 2009-2014
Table 13: Global Population, by Select Country, 2017 and 2022
Table 14: Global Population, Age 65+, by Select Country, 2017 and 2022
Table 15: Global Life Expectancy at Birth, by Select Country, 1980, 2010 and 2020 Projections (Both Genders Combined)
Table 16: Global Non-opioid Pain Treatment Market, by Product Segment, Through 2022
Table 17: Global Market Shares of Non-opioid Pain Treatments, by Product Segment, 2017
Table 18: Selected Cannabis Clinical Trials for Pain Treatment
Table 19: Global Medical Cannabis Pain Treatment Market by Indication, Through 2022
Table 20: Global Market Shares of Medical Cannabis Pain Treatments, by Indication, 2017
Table 21: Selected Capsaicin-derived Clinical Trials for Pain Treatment
Table 22: Global Capsaicin-derived Pain Treatment Market, by Indication, Through 2022
Table 23: Global Market Shares of Capsaicin-derived Pain Treatments, by Indication, 2017
Table 24: Selected Menthol-containing Clinical Trials for Pain Treatment
Table 25: Global Menthol-containing Pain Treatment Market, by Indication, Through 2022
Table 26: Global Market Shares of Menthol-containing Pain Treatments, by Indication, 2017
Table 27: Selected Omega-3 Fatty Acid-containing Clinical Trials for Pain Treatment
Table 28: Global Omega-3 Fatty Acid-containing Pain Treatment Market, by Indication, Through 2022
Table 29: Global Market Shares of Omega-3 Fatty Acid-containing Pain Treatments, by Indication, 2017
Table 30: U.S. Market for Allergan’s Botox, by Treatment Area, 2016
Table 31: U.S. Market for Allergan’s Botox, by Treatment Area, 2017
Table 32: Selected Botulinum Toxin Clinical Trials for Pain Treatment
Table 33: Global Botulinum Toxin Pain Treatment Market, by Indication, Through 2022
Table 34: Global Market for Botulinum Toxin Pain Treatments, by Indication, 2017
Table 35: Global Non-opioid Pain Treatment Market, by Therapeutic Application, Through 2022
Table 36: Global Market Shares of Non-opioid Pain Treatments, by Therapeutic Application, 2017
Table 37: Global Non-opioid Cancer Pain Treatment Market, by Product Segment, Through 2022
Table 38: Global Market Shares of Non-opioid Cancer Pain Treatments, by Product Segment, 2017
Table 39: Global Market Shares of Non-opioid Cancer Pain Treatments, by Cancer Type, 2017
Table 40: Global Non-opioid Neuropathic Pain Treatment Market, by Product Segment, Through 2022
Table 41: Global Market Shares of Non-opioid Neuropathic Pain Treatments, by Product Segment, 2017
Table 42: Global Market Shares of Non-opioid Neuropathic Pain Treatments, by Disease/Disorder Type, 2017
Table 43: Global Non-opioid Orthopedic/Musculoskeletal Pain Treatment Market, by Product Segment, Through 2022
Table 44: Global Market Shares of Non-opioid Orthopedic/Musculoskeletal Pain Treatments, by Product Segment, 2017
Table 45: Global Market Shares of Non-opioid Orthopedic/Musculoskeletal Pain Treatments, by Disease/Disorder Type, 2017
Table 46: Global Market for Other Non-opioid Pain Treatments, by Product Segment, Through 2022
Table 47: Global Market Shares of Other Non-opioid Pain Treatments, by Product Segment, 2017
Table 48: Global Market Shares of Other Non-opioid Pain Treatments, by Disease/ Disorder Type, 2017
Table 49: Global Non-opioid Pain Treatment Market, by Region, Through 2022
Table 50: Global Market Shares of Non-opioid Pain Treatments, by Region, 2017
Table 51: Regional Grouping: Countries, by Region
Table 52: North American Non-opioid Pain Treatment Market, by Country, Through 2022
Table 53: EMEA Non-opioid Pain Treatment Market, by Country, Through 2022
Table 54: Asia-Pacific Non-opioid Pain Treatment Market, by Country, Through 2022
Table 55: Latin American Non-opioid Pain Treatment Market, by Country, Through 2022
Table 56: U.S. Patents Related to Medical Cannabis, by Type, Through 2017
Table 57: U.S. Patents on Medical Cannabis Technologies, by Type, Through 2017
Table 58: Notable U.S. Patents Related to Medical Cannabis, by Company, Through 2017
Table 59: List of U.S. Patents Related to Medical Cannabis, July 2017-Nov. 2017
Table 60: Notable Developments in Non-opioid Pain Relief, Through 2017
Table 61: Glossary of Terms Used in Non-opioid Pain Treatment
Table 62: Global Pain Societies and Organizations
Table 63: Report Sources

List of Figures:
Summary Figure: Global Market for Non-opioid Pain Treatments, by Product Segment, 2016-2022
Figure 1: Non-opioid Pain Management Market Drivers and Restraints
Figure 2: Pain Management Techniques
Figure 3: Total Hospice Patients Served, by Year, 2009-2014
Figure 4: Distribution of Causes of Mortality and Potential Need for Palliative Care, 2017
Figure 5: Global Population, by Country, 2017 and 2022
Figure 6: Global Population Age 65+, by Country, 2017 and 2022
Figure 7: Global Life Expectancy at Birth, by Select Country, 1980, 2010 and 2020 Projections
Figure 8: Global Non-opioid Pain Treatment Market, by Product Segment, 2016-2022
Figure 9: Global Market Shares of Non-opioid Pain Treatments, by Product Segment, 2017
Figure 10: Global Market Shares of Medical Cannabis: Pain vs. All Other Uses, 2017
Figure 11: Global Medical Cannabis Pain Treatment Market, by Indication, 2016-2022
Figure 12: Global Market Shares of Medical Cannabis Pain Treatments, by Indication, 2017
Figure 13: Global Capsaicin-derived Pain Treatment Market, by Indication, 2016-2022
Figure 14: Global Market Shares of Capsaicin-derived Pain Treatments, by Indication, 2017
Figure 15: Global Menthol-containing Pain Treatment Market, by Indication, 2016-2022
Figure 16: Global Market Shares of Menthol-containing Pain Treatments, by Indication, 2017
Figure 17: Global Omega-3 Fatty Acid-containing Pain Treatment Market, by Indication, 2016-2022
Figure 18: Global Market Shares of Omega-3 Fatty Acid-containing Pain Treatments, by Indication, 2017
Figure 19: Global Botulinum Toxin Pain Treatment Market, by Indication, 2016-2022
Figure 20: Global Market Shares of Botulinum Toxin Pain Treatments, by Indication, 2017
Figure 21: Global Non-opioid Pain Treatment Market, by Therapeutic Application, 2016-2022
Figure 22: Global Market Shares of Non-opioid Pain Treatments, by Therapeutic Application, 2017
Figure 23: Global Non-opioid Cancer Pain Treatment Market, by Product Segment, 2016-2022
Figure 24: Global Market Shares of Non-opioid Cancer Pain Treatments, by Product Segment, 2017
Figure 25: Global Market Shares of Non-opioid Cancer Pain Treatments, by Cancer Type, 2017
Figure 26: Global Non-opioid Neuropathic Pain Treatment Market, by Product Segment, 2016-2022
Figure 27: Global Market Shares of Sales of Non-opioid Neuropathic Pain Treatments, by Product Segment, 2017
Figure 28: Global Market Shares of Non-opioid Neuropathic Pain Treatments, by Disease/Disorder Type, 2017
Figure 29: Global Non-opioid Orthopedic/Musculoskeletal Pain Treatment Market, by Product Segment, 2016-2022
Figure 30: Global Market Shares of Non-opioid Orthopedic/Musculoskeletal Pain Treatments, by Product Segment, 2017
Figure 31: Global Market Shares of Non-opioid Orthopedic/Musculoskeletal Pain Treatments, by Disease/Disorder Type, 2017
Figure 32: Global Market for Other Non-opioid Pain Treatments, by Product Segment, 2016-2022
Figure 33: Global Market Shares of Other Non-opioid Pain Treatments, by Product Segment, 2017
Figure 34: Global Market Shares of Other Non-opioid Pain Treatments, by Disease/ Disorder Type, 2017
Figure 35: Global Non-opioid Pain Treatment Market, by Region, 2016-2022
Figure 36: Global Market Shares of Non-opioid Pain Treatments, by Region, 2017
Figure 37: North American Non-opioid Pain Treatment Market, by Country, 2016-2022
Figure 38: North American Market Shares of Alternative Non-opioid Pain Treatments, by Country, 2017
Figure 39: Canadian Market Shares of Alternative Non-opioid Pain Treatments, by Product Segment, 2017
Figure 40: Canadian Market Shares of Alternative Non-opioid Pain Treatments, by Application, 2017
Figure 41: Canadian Market Shares of Alternative Non-opioid Pain Treatments, by Product Segment, 2017
Figure 42: Canadian Market Shares of Alternative Non-opioid Pain Treatments, by Application, 2017
Figure 43: EMEA Non-opioid Pain Treatment Market, by Country, 2016-2022
Figure 44: EMEA Market Shares of Alternative Non-opioid Pain Treatments, by Country, 2017
Figure 45: French Market Shares of Alternative Non-opioid Pain Treatments, by Product Segment, 2017
Figure 46: French Market Shares of Alternative Non-opioid Pain Treatments, by Application, 2017
Figure 47: German Market Shares of Alternative Non-opioid Pain Treatments, by Product Segment, 2017
Figure 48: German Market Shares of Alternative Non-opioid Pain Treatments, by Application, 2017
Figure 49: Italian Market Shares of Alternative Non-opioid Pain Treatments, by Product Segment, 2017
Figure 50: Italian Market Shares of Alternative Non-opioid Pain Treatments, by Application, 2017
Figure 51: Russian Market Shares of Alternative Non-opioid Pain Treatments, by Product Segment, 2017
Figure 52: Russian Market Shares of Alternative Non-opioid Pain Treatments, by Application, 2017
Figure 53: Spanish Market Shares of Alternative Non-opioid Pain Treatments, by Product Segment, 2017
Figure 54: Spanish Market Shares of Alternative Non-opioid Pain Treatments, by Application, 2017
Figure 55: U.K. Market Shares of Alternative Non-opioid Pain Treatments, by Product Segment, 2017
Figure 56: U.K. Market Shares of Alternative Non-opioid Pain Treatments, by Application, 2017
Figure 57: Asia-Pacific Non-opioid Pain Treatment Market, by Country, 2016-2022
Figure 58: Asia-Pacific Market Shares of Alternative Non-opioid Pain Treatments, by Country, 2017
Figure 59: Australia/New Zealand’s Market Shares of Alternative Non-opioid Pain Treatments, by Product Segment, 2017
Figure 60: Australia/New Zealand’s Market Shares of Alternative Non-opioid Pain Treatments, by Application, 2017
Figure 61: Chinese Market Shares of Alternative Non-opioid Pain Treatments, by Product Segment, 2017
Figure 62: Chinese Market Shares of Alternative Non-opioid Pain Treatments, by Application, 2017
Figure 63: Japanese Market Shares of Alternative Non-opioid Pain Treatments, by Product Segment, 2017
Figure 64: Japanese Market Shares of Alternative Non-opioid Pain Treatments, by Application, 2017
Figure 65: Latin American Non-opioid Pain Treatment Market, by Country, 2016-2022
Figure 66: Latin American Market Shares of Alternative Non-opioid Pain Treatments, by Country, 2017
Figure 67: Argentinean Market Shares of Alternative Non-opioid Pain Treatments, by Product Segment, 2017
Figure 68: Argentinean Market Shares of Alternative Non-opioid Pain Treatments, by Application, 2017
Figure 69: Brazilian Market Shares of Alternative Non-opioid Pain Treatments, by Product Segment, 2017
Figure 70: Brazilian Market Shares of Alternative Non-opioid Pain Treatments, by Application, 2017
Figure 71: Mexican Market Shares of Alternative Non-opioid Pain Treatments, by Product Segment, 2017
Figure 72: Mexican Market Shares of Alternative Non-opioid Pain Treatments, by Application, 2017
Figure 73: Total U.S. Patents on Non-opioid Pain Treatments, by Type, Through 2017
Figure 74: Shares of U.S. Patents Related to Medical Cannabis, by Type, Through 2017
Figure 75: Shares of U.S. Patents on Medical Cannabis Technologies, by Type, Through 2017
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Allergan PLC
  • Aurora
  • Canopy Growth Corp.
  • Centrexion Therapeutics
  • Cronos Group
  • Medical Marijuana Inc.
  • MORE
Scope of Report

This report is designed to be a helpful business tool that will provide a thorough evaluation of the markets for pain management. The geographical scope of this study is global. This study addresses acute versus chronic pain, treatments and regulatory issues facing healthcare workers. Also provided is detailed information based on product categories, use of products, forecasts and competitive analyses.

The report identifies five general product segments for non-opioid treatment of pain:
  • Medical cannabis treatments.
  • Capsaicin-derived treatments.
  • Menthol-containing treatments.
  • Omega 3 fatty acid-containing treatments.
  • Botulinum toxins.
Within the segment several sub-segments are discussed as they pertain to each product segment; diseases or disorders are the basis for these sub-segments, including:
  • Arthritis.
  • Cancer?brain, breast, colorectal, leukemia/lymphoma, melanoma, prostate, others.
  • Dental.
  • Epilepsy.
  • Fibromyalgia.
  • Migraine.
  • Multiple sclerosis.
  • Surgical.
A regional analysis of these product segments is also provided, including the specific countries listed below and including countries not listed as a “rest of the world” market.
  • Argentina.
  • Australia/New Zealand.
  • Brazil.
  • Canada.
  • China.
  • France.
  • Germany.
  • Italy.
  • Japan.
  • Mexico.
  • Russia.
  • Spain.
  • United Kingdom.
  • United States.
Each market segment provides detailed information based on product categories, product use, current market value and forecasts.

Not covered in the report are drugs or devices that are considered “conventional” in professional treatment guidelines that are due to either controversial issues such as those with medical cannabis or those that are not commonly prescribed or recommended due to a lack of clinical data, education or other factors.

Reasons for Doing This Study

This study will provide the reader with the knowledge to adequately view and assess alternative areas of pain treatment that are penetrating the conventional pain treatment market. In response to the new treatment areas, the industry is faced with unprecedented challenges regarding patient quality of life, treatment liability and government limitations and compliance. The study provides insights into the market potential in the segments discussed in the report as these areas are the most pressing in terms of their potential benefits and how they compare when being evaluated against prescription opioid therapies.

The report is designed to provide the reader with a background of the pain management industry and current factors influencing growth and provide decision-makers with the tools to make decisions regarding expanding into the newest areas of pain management treatment in regard to non-opioid treatments.
Note: Product cover images may vary from those shown
5 of 6
  • Allergan PLC
  • Aphria Inc.
  • Aurora
  • Bedrocan
  • Canopy Growth Corp.
  • Cara Therapeutics
  • Centrexion Therapeutics
  • CHT Medical
  • Cronos Group
  • GW Pharmaceuticals
  • Medical Marijuana Inc.
  • Medropharm Gmbh
  • Panag Pharma Inc.
  • Tilray
  • US Worldmeds LLC
  • Vanway
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll